ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
AZ’ HER2 drug hits mid-stage trial endpoints pharmatimes
May 28, 2019AstraZeneca’s HER2-targeting antibody drug conjugate (ADC), DS-8201 (trastuzumab deruxtecan), demonstrated a clinically meaningful response in patients with refractory HER2-positive metastatic breast cancer.
Pharma Sources Insight July 2025
